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ABSTRACT
The oncoprotein v-Myb of avian myeloblastosis
virus (AMV) transforms myelomonocytic cells by
deregulating specific target genes. Previous work
has shown that the oncogenic potential of v-Myb
was activated by truncation of N- and C-terminal
sequences of c-Myb and was further increased by
amino acid substitutions in the DNA-binding domain
and other parts of the protein. We have analyzed the
activation of the chicken lysozyme gene which is
strongly activated by c-Myb but not by its oncogenic
counterpart v-Myb. We report that Myb acts on two
different cis-regulatory elements, the promoter and
an enhancer located upstream of the gene.
Interestingly, the activation of the enhancer was
abolished by the oncogenic amino acid substitu-
tions. We demonstrated that a single Myb-binding
site is responsible for the activation of the lysozyme
enhancer by Myb and showed that the v-Myb protein
of AMV was unable to bind to this site. Our data
demonstrate for the first time that oncogenic
activation of Myb alters its DNA-binding specificity
at a physiological Myb target gene.
INTRODUCTION
Myb proteins constitute a family of related transcription
factors that play important roles in the control of
proliferation and diﬀerentiation of various cell types
(1–3). The founding member of this family, v-Myb, was
originally identiﬁed as the protein encoded by the retro-
viral oncogene v-myb of avian myeloblastosis virus
(AMV) (4). v-myb is a truncated and mutated derivative
of the chicken c-myb gene and is responsible for the ability
of AMV to transform myeloid cells in vivo and in vitro.
c-myb is not oncogenic but plays a key role in the
development of the hematopoietic system. A large body of
work has demonstrated that c-myb is highly expressed in
immature, proliferating hematopoietic cells and is down-
regulated during their terminal diﬀerentiation (1–3).
Constitutive expression of c-myb blocks hematopoietic
diﬀerentiation whereas disruption of the gene in mice
leads to defects of multiple hematopoietic lineages and
embryonic death (5). It is thought that c-myb acts as a
genetic switch in hematopoietic progenitor cells that
controls alternative cell fates, such as proliferation,
diﬀerentiation and apoptosis (6). v-myb disrupts the
normal control of these processes and thereby transforms
cells of the myelomonocytic lineage.
v-Myb and c-Myb are nuclear DNA-binding proteins
that recognize a speciﬁc sequence motif (7) and regulate
the activity of promoters that contain this motif (8–11).
By using diﬀerent approaches, such as diﬀerential screen-
ing of cells transformed by a temperature-sensitive mutant
of v-myb (10), diﬀerential display of RNA from cells
expressing estrogen-inducible or dominant-interfering
versions of v-Myb or c-Myb (12–14) or microarray-
based expression analyses (15,16) a substantial number of
Myb-regulated genes have been identiﬁed. However,
although a large number of potential Myb target genes
are now known, the role of these genes in cell transforma-
tion and hematopoietic diﬀerentiation, and the molecular
mechanisms by which Myb proteins regulate their expres-
sion, are only beginning to be understood.
Detailed studies on how Myb aﬀects the expression of
its targets have been performed only in a few cases. One of
the most thoroughly studied Myb target gene is the
chicken mim-1 gene (10). Because mim-1 is only tran-
scribed in myelomonocytic cells and because it is induced
to very high expression levels by Myb, mim-1 has been an
attractive model to study how Myb activates target genes
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strated that Myb cooperates with members of the
CCAAT-box/enhancer-binding protein (C/EBP) family
to activate mim-1 expression (17,18). Furthermore, it
was shown that c-Myb activates the mim-1 gene by
binding not only to the promoter but also to a myeloid-
speciﬁc enhancer located upstream of the gene (19).
The oncogenic potential of v-Myb is primarily due to
N- and C-terminal truncations that have occurred during
transduction of myb sequences into the AMV genome (20).
In addition to these truncations, v-Myb harbors several
amino acid substitutions which have been acquired during
the repeated passage of the virus in leukemic chickens and
are scattered throughout the protein. It has been shown
that these amino acid substitutions, some of which are
located in the DNA-binding domain of the protein,
strongly enhance the oncogenic potential of Myb (20).
Furthermore, these substitutions have profound eﬀects on
the phenotype of the transformed cells and on which genes
are activated by v-Myb. This has initially been observed
with the mim-1 and lysozyme genes, both of which are
direct targets of c-Myb but cannot be activated by v-Myb
as a result of amino acid substitutions in the DNA-binding
domain of v-Myb (10,21). More recently a large number of
genes have been identiﬁed whose regulation by Myb
depends on the presence of some or all of the AMV-
speciﬁc amino acid substitutions (16). On the molecular
level, the amino acid substitutions within the DNA-
binding domain of v-Myb appear to aﬀect the activity of
the protein in several ways. They were reported to disrupt a
negative regulatory mechanism that is triggered by
conformational changes catalyzed by the peptidyl-prolyl-
isomerase Cyp-40 (22). In addition, it has been suggested
that the amino acid substitutions have abrogated the
ability of v-Myb to cooperate with the CCAAT-box/
enhancer-binding protein C/EBPb (23) and to interact with
the aminoterminal tail of histone H3 and thereby facilitate
histone tail acetylation (24). In case of the chicken mim-1
gene we have shown that the substitutions aﬀect the
cooperation of the promoter of the gene with a Myb-
inducible enhancer (19). Surprisingly, although several
of the oncogenic amino acid substitutions are located
within the DNA-binding domain, there is no evidence
as yet that they aﬀect the binding of the protein to
physiological target sites.
Here, we have compared the regulation of the myeloid-
speciﬁc chicken lysozyme gene by v-Myb and by a v-Myb
variant lacking most of the oncogenic amino acid
substitutions. Our work shows that Myb acts on two
diﬀerent cis-regulatory sequences of the lysozyme gene,
the promoter and an enhancer located 2.7kb upstream of
the gene, and employs C/EBPa and PU.1 as cooperation
partners. Interestingly, the oncogenic amino acid substitu-
tions abolish the ability of v-Myb to stimulate the
enhancer. We show that the activation of the enhancer
by Myb depends on a single Myb-binding site whose
recognition is abrogated by the oncogenic amino acid
substitutions in the DNA-binding domain of v-Myb. Our
data demonstrate for the ﬁrst time that oncogenic
activation of Myb results in altered DNA-binding proper-
ties of Myb at a physiological target gene.
MATERIALS AND METHODS
Cells
HD11 is a line of MC29 transformed chicken macro-
phages and was grown in basal Iscoves’ medium
supplemented with 8% fetal calf serum and 2% chicken
serum. QT6 is a line of Japanese quail ﬁbroblasts and was
grown in basal Iscoves’ medium supplemented with 8%
fetal calf serum and 2% chicken serum (17). A doxycyclin-
inducible expression vector for v-Myb was generated by
subcloning the coding region for v-Myb from plasmid
pCDE26v-myb (25) as a HindIII/XbaI DNA fragment
into pCDNA4/TO/myc-His-A (Invitrogen). The resulting
plasmid was then transfected together with pCDNA6-TR
(which encodes the tet-repressor) into HD11 cells,
followed by selection of stable transfectants in the
presence of 750mg/ml zeocin and 750mg/ml blasticidin.
Doxycyclin was omitted during the selection procedure to
prevent v-Myb expression. Doubly-resistant stable cell
clones were then analyzed by western blotting for
doxycyclin-inducible expression of the v-Myb protein.
Clone HD11-E was selected for further analysis.
Reporter genes, expression vectors and transfections
Chicken lysozyme reporter genes pCL2000 (containing
lysozyme promoter sequences from  579 to +15),
pCL2000-2.7, pTATA-2.7, pTATA-3.9, pTATA-6.1 and
the pTATA vector have been described before (26).
A truncated version of the enhancer (referred to as min-
Enh) was generated by PCR using the primers
50-CATAAGCTTGGCAGATGACTATGACTACT-30
and 50-CATGGATCCTCCTGCTTTGCAATTCAGAA-30
followed by subcloning of the PCR fragment into pTATA
via HindIII and BamHI sites. Point mutants of the
 2.7kb enhancer were generated by PCR in the plasmid
pTATA-2.7 using the appropriate primers. In plasmid
pTATA-2.7mut1a Myb-binding site (underlined) was
changed from TCTGCAGTTGGCAG to TCTGCAG
CCGGCAG. In plasmid pTATA-2.7mut2a Myb-binding
site (underlined) was changed from TGAG
GAACTAGCTG to TGAGGGACTAGCTG. In plasmid
pTATA-2.7mut3 a Myb-binding site (underlined) was
changed from ATTTCTGTTTGACCA to ATTTCTG
GGTGACCC. In plasmid pTATA-2.7mut4 a Myb-
binding site (underlined) was changed from GCAG
GAGTTAGCGG to GCAGGAGTCAGCGG. In plas-
mid pTATA-2.7mutCEBP a C/EBP-binding site (under-
lined) was changed from TGGTATTTGGAAATAATA
to TGGTACCTGGACCTAATA. All constructs were
veriﬁed by sequencing. The b-galactosidase reporter gene
pCMVb was obtained from Clontech. An expression
vector for AMV v-Myb (pCDAMVv-myb) has been
described (19). pCDE26v-myb is a derivative of
pCDAMVv-myb generated by replacing the v-myb
coding region between the NcoI and SalI sites of v-myb
with the corresponding sequence from c-myb. Expression
vectors for chicken C/EBPa (pCDNA3-chC/EBPa),
chicken C/EBPb (pCDNA3-CCR) and PU.1
(pCDmPu.1) have been described before (25). DNA
transfection was performed by calcium-phosphate
7238 Nucleic Acids Research, 2007, Vol. 35, No. 21co-precipitation as described previously (17). The
preparation of cell extracts, luciferase and b-galactosidase
assays were performed as described (17).
Chromatin immunoprecipitation
Chromatin immunoprecipitation was performed as fol-
lows: approximately 10
8 cells were incubated for 10min at
room temperature with growth medium containing 1%
formaldehyde and quenched by adding glycine (125mM
ﬁnal concentration) and incubating for 5min. After
washing twice with ice-cold phosphate-buﬀered saline
cells were suspended in RIPA buﬀer (10mM Tris–HCl,
pH 7.8; 50mM NaCl; 1mM PMSF; 0.5% sodium
deoxycholate; 0.5% NP40; 0.1% SDS) and sonicated on
ice (5s pulsed intervals for 3min). After centrifugation for
10min at 14000r.p.m. the extract was pre-incubated with
protein-A sepharose for 1h at 48C. The supernatant was
then incubated with Myb-speciﬁc rabbit antisera raised
against a bacterially expressed Myb protein lacking the
DNA-binding domain (4) or against the DNA-binding
domain of v-Myb (29), normal rabbit serum or no
antiserum, overnight at 48C on a rotating wheel.
Samples were then incubated with protein-A sepharose
for 1h and washed in ELB buﬀer (50mM Tris–HCl, pH
7.5; 120mM NaCl; 1mM EDTA; 6mM EGTA; 15mM
sodium pyrophosphate; 20mM sodium ﬂuoride; 1mM
PMSF; 0.5% NP40) (three washes), with ELB buﬀer
supplemented with 250mM LiCl (two washes), with ELB
buﬀer supplemented with 250mM LiCl and 0.1% SDS
(one wash) and two ﬁnal washes with ELB buﬀer. The
immunoprecipitates were eluted ﬁrst with elution buﬀer 1
(100mM NaHCO3) and then with elution buﬀer 2 (10mM
Tris–HCl, 1mM EDTA; 1% SDS; 10mM DTT). The
eluates were combined and after addition of Proteinase K
(500mg/ml ﬁnal concentration) the DNA was reverse
cross-linked by incubation for 12h at 658C. Finally,
the immunoprecipitated DNA was extracted by phenol–
chloroform, ethanol precipitated, resuspended in
50–100ml of water and stored at  208C. PCR was
performed by using the following primers. Lysozyme
promoter: 50-CTGATGATGAACAATGGCTATG-30
and 50-CCCTTTGATTCCTCTGTTCTACA-30, lysozyme
 2.7kb enhancer: 50-CACTCCCACACTGAAACAA
CA-30 and 50-TTTTTATCCTCTTCCTTGTAAGCAG-30.
PCR products were resolved on 2% agarose gels and
stained with ethidium bromide.
Electrophoretic mobility shiftassays
Pairs of complementary single-stranded oligonucleotides
containing wild-type (wt) or mutated Myb-binding sites
were annealed and used for gel retardation assays:
MBS3wt: 50-GGCTGGGAATATTTCTGTTTGACCAC
CATGGAG-30 and 50-CTCCATGGTGGTCAAACAGA
AATATTCCCAGC-30; MBS3mut: 50-GGCTGGGAAT
ATTTCTGGGTGACCACCATGGAG-30 and 50-CTCC
ATGGTGGTCACCCAGAAATATTCCCAGC-30;m i m A :
50-GCTCTAAAAAACCGTTATAATGTACAGATATC
TT-30 and 50-AAGATATCTGTACATTATAACGGTTT
TTTAGAG-30. After annealing, oligonucleotides were
radiolabeled by ﬁlling in the ends using a
32P-dCTP and
Klenow polymerase. Bacterial v-Myb, using the expres-
sion vector pVM2028 and pVM2101, was prepared and
binding experiments were performed as described (30).
pVM2028 encodes the v-Myb protein of AMV and has
been described (31). pVM2101 is a derivative of pVM2028
generated by replacing the v-myb coding region between
the NcoI and SalI sites of v-myb with the corresponding
sequence from c-myb. As a result, several of the amino
acid substitutions harbored by the DNA-binding domain
of AMV v-Myb were reverted to the sequences found in
the DNA-binding domain of c-Myb.
RESULTS
Mybstimulates the activity ofthe promoter and an enhancer
ofthe chicken lysozyme gene
To understand how Myb activates the expression of the
chicken lysozyme gene we analyzed the inﬂuence of Myb
on luciferase reporter genes containing the promoter or
known cis-regulatory sequences of the chicken lysozyme
gene. We used an expression vector encoding a modiﬁed
version of v-Myb in which most of the AMV-speciﬁc
amino acid substitutions had been reverted by replacing
part of the coding region with the corresponding sequence
of the c-myb gene. The structure of this modiﬁed v-Myb
(referred to as v-Myb
REV) is shown schematically in
Figure 1E. We have shown before that this modiﬁed
version of v-Myb activates the endogenous chicken
lysozyme gene, in contrast to v-Myb
AMV, which does
not activate the gene (12). Reporter gene experiments were
performed in the myelomonocytic cell line HD11 which
lacks endogenous v-Myb or c-Myb. As shown in
Figure 1A, v- Myb
REV strongly activated the lysozyme
promoter and the reporter gene containing the  2.7kb
lysozyme enhancer. The  6.1kb lysozyme enhancer was
weakly activated and the  3.9kb enhancer was not
activated at all. We also performed experiments in parallel
with the expression vector for v-Myb
AMV, reasoning that
the direct comparison of the eﬀects of both versions of
v-Myb might provide clues about why the AMV version
of v-Myb does not activate the lysozyme gene. As shown
in Figure 1B, both Myb proteins displayed similar
activities with the notable exception of the  2.7kb
enhancer which was not aﬀected signiﬁcantly by
v-Myb
AMV. This diﬀerence was not due to diﬀerent
expression levels of both proteins (Figure 1D). Taken
together, these experiments identiﬁed the promoter and
the  2.7kb enhancer as major Myb-responsive elements
of the lysozyme gene. In addition, they demonstrated that
the two versions of v-Myb display signiﬁcantly diﬀerent
activities at the  2.7kb lysozyme enhancer. These
diﬀerences were also observed when co-transfections
were performed in a ﬁbroblast cell line, conﬁrming that
the presence of the amino acid substitutions in v-Myb
AMV
has abolished the ability of the protein to stimulate the
 2.7kb enhancer (Figure 1C).
To conﬁrm that Myb targets two diﬀerent cis-acting
regions of the lysozyme gene we performed chromatin
immunoprecipitation experiments using a stable transfec-
tant of the myelomonocytic HD11 cell line in which the
Nucleic Acids Research, 2007, Vol. 35, No. 21 7239expression of v-Myb
REV is induced by growing the cells in
the presence of doxycyclin. Western blotting showed that
the Myb protein was expressed in the presence but not
in the absence of doxycyclin (Figure 2A). The chromatin
immunoprecipitation experiment illustrated in Figure 2B
conﬁrmed the binding of Myb to the lysozyme promoter
and the  2.7kb enhancer following induction by dox-
ycyclin. This experiment, therefore, supported the notion
that Myb activates the lysozyme gene by targeting two
diﬀerent regions of the gene.
Myb synergizes withPU.1 andC/EBPaat the 2.7kb
lysozyme enhancer
The diﬀerential activity of v-Myb
REV and v-Myb
AMV at
the  2.7kb enhancer suggested that further analysis of the
enhancer might provide a clue about why the AMV
version of v-Myb does not activate the lysozyme gene.
Several proteins have previously been implicated in
binding to the  2.7kb lysozyme enhancer, including Ets
and C/EBP family members as well as an unknown
protein binding to an ‘AP-1-like’ site (26,32,33). The
protein binding to the Ets-binding site has been tentatively
identiﬁed as PU.1 (26,33). To explore whether Myb
cooperates with one of the known proteins that bind to
the enhancer we performed co-transfection experiments
with diﬀerent combinations of expression vectors for
Myb, PU.1, C/EBPa and C/EBPb (Figure 3A). Herschlag
and Johnson (34) deﬁned synergism in transcriptional
activation as existing when the eﬀects of two factors are
more than additive. To determine whether Myb is
synergistic with any of the other factors we therefore
compared the activity of the reporter gene, in the presence
of each factor alone, to the activity observed when the
same factors were expressed together. When transfected
on its own, each of the factors was able to stimulate the
activity of the enhancer to some extent. When expressed
together, more than additive stimulation was observed
when Myb was combined with C/EBPa or with PU.1,
whereas merely additive stimulation was observed when
Myb was combined with C/EBPb. The degree of synergy
is expressed in a quantitative manner by the numbers on
top of the columns in Figure 3A, where a factor larger
than one indicates more than additive eﬀects. From these
numbers it is apparent that C/EBPa and PU.1 synergize
with Myb according to the deﬁnition of Herschlag and
Johnson (34) whereas Myb and C/EBPb are not synergis-
tic. We also assessed the combined eﬀects of C/EBPa and
PU.1, and of Myb, C/EBPa and PU.1 on the enhancer
(Figure 3B). Interestingly, C/EBPa and PU.1 did not act
synergistically in the absence of Myb whereas the presence
of Myb resulted in a very strong stimulation of the
enhancer activity. Thus, it appears that Myb, C/EBPa and
PU.1 act in concert to activate the lysozyme enhancer.
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Figure 1. Myb-dependent activity of chicken lysozyme reporter genes.
The lysozyme gene upstream region is shown schematically at the top.
Black boxes indicate the promoter (P) or enhancer sequences
(numbered boxes) that are covered by reporter genes. (A, B) HD11
cells were transfected with the indicated reporter genes and expression
vector for v-Myb
REV (black columns) or empty vector (white columns).
To control the transfection eﬃciency cells were additionally transfected
with the b-galactosidase plasmid pCMVb. Cells were analyzed for
luciferase and b-galactosidase activities 24h after transfection. The
columns show the average luciferase activity (arbitrary units) normal-
ized to the b-galactosidase activity. Thin lines show standard
deviations. Panel B shows an identical experiment except that
expression vector for v-Myb
AMV was used. (C) QT6 cells with the
indicated reporter genes and expression vectors for v-Myb
AMV (hatched
columns), v-Myb
REV (black columns) or empty expression vector (white
columns). (D) Western blot of cells transfected with expression vectors
for v-Myb
AMV (lane 1) and v-Myb
REV (lane 2) using Myb-speciﬁc
antiserum (28). The arrow marks the v-Myb protein. (E) Schematic
illustration of the structure of v-Myb
AMV and v-Myb
REV. Arrows mark
point mutations of v-Myb
AMV relative to c-Myb. The three point
mutation in the DNA-binding domain (DBD) that aﬀects the ability of
v-Myb to activate the lysozyme gene are highlighted with the
numbering referring to c-Myb.
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with Myb in the context of other Myb-regulated genes,
such as the mim-1 and tom-1 genes (17,35). However,
pronounced diﬀerences in their ability to synergize with
Myb have not been observed so far. We wondered
whether the disparate behavior of both C/EBPs was due
to subtle diﬀerences in their DNA-binding speciﬁcities. To
address this issue we used expression vectors for recombi-
nants of C/EBPa and C/EBPb whose DNA-binding
domains had been exchanged (see top of Figure 3C).
The transactivation experiment illustrated in Figure 3C
showed that the ability to synergize with Myb was
dependent on the transactivation domain of C/EBPa.I t
is therefore unlikely that diﬀerences in DNA binding
between C/EBPa and C/EBPb are responsible for their
diﬀerent behavior. The diﬀerences in activity of C/EBPa
and b at the  2.7kb enhancer and the promoter of the
lysozyme gene were reminiscent of previous work in which
we had shown that ectopic expression of Myb and C/
EBPa, but not of C/EBPb, activated the endogenous
lysozyme gene in chicken ﬁbroblasts (17).
A singleMyb-binding site isresponsible for theactivation
of the 2.7kbenhancer by Myb
To further understand the mechanism by which Myb
activates the  2.7kb lysozyme enhancer we examined the
enhancer for Myb-binding sites which mediate the
stimulation by Myb. As a ﬁrst step we performed a
transactivation experiment using a mutant of v-Myb
REV
which lacks DNA-binding activity. In this mutant a single
amino acid residue (Asp186), which is directly involved in
contacts with speciﬁc bases of the Myb recognition motif
and has been shown to be crucial for the speciﬁc DNA-
binding activity of Myb (36,37), was mutated to alanine.
As shown in Figure 4A, the mutant Myb protein failed to
stimulate the enhancer, consistent with the notion that one
or several Myb-binding sites mediate the eﬀect of Myb.
We then examined the sequence of the enhancer for
potential Myb-binding sites. There are four GTT-
(or AAC- in the reverse orientation) motifs within the
enhancer sequence, which conform to the central core of
the Myb-binding site. One of these motifs (designated as
site 1 in Figure 4B) showed a good match to the Myb
consensus site (PyAACT/GG) whereas the other sites were
more distantly related. We mutated each of these motifs
and examined the ability of v-Myb
REV to activate the
mutated enhancers. Figure 4B shows that only mutation
of site 3 signiﬁcantly reduced the stimulation of the
enhancer by Myb. This suggested that binding site 3 plays
a key role in the Myb-dependent activation of the
enhancer. We also constructed a truncated version of the
enhancer and found that its stimulation by v-Myb
REV was
essentially identical to that of the full-length enhancer
(Figure 4C).
Myb-binding site 3 is situated between the Ets- and C/
EBP-binding sites (see top of Figure 4B). We were
therefore interested to know whether this site mediates
the synergistic cooperation of Myb with PU.1 and C/
EBPa. To address this we examined the eﬀect of mutation
of the Myb, PU.1 and C/EBP-binding sites on the ability
of these transcription factors to synergize. We employed
the MBS2 mutant to ascertain the role of the PU.1-
binding site because mutation of Myb-binding site 2 had
also destroyed the PU.1-binding site. Figure 5A shows
that mutation of the PU.1-binding site abolished the
ability of PU.1 to activate the enhancer and to synergize
with Myb, conﬁrming that this site mediates the eﬀect of
PU.1 on the enhancer. Mutation of Myb-binding site 3
had no eﬀect on the ability of PU.1 to activate the
enhancer in the absence of Myb but abrogated the
synergistic eﬀect of Myb and PU.1. Figure 5B shows
that mutation of the C/EBP-binding site prevented
C/EBPa from activating the enhancer and from synergiz-
ing with Myb, indicating that this site mediates the eﬀect
of C/EBPa on the enhancer. Mutation of Myb-binding
site 3 did not aﬀect the activation of the enhancer by
C/EBPa but diminished the ability of Myb and C/EBPa to
synergize. However, it did not completely abolish the
synergy between Myb and C/EBPa, possibly because there
was still residual binding of Myb to the mutant site. Taken
together, the data presented in Figures 3–5 indicate that
Myb activates the  2.7kb lysozyme enhancer by binding
to Myb-binding site 3 and cooperating with Pu.1 and
C/EBPa bound to their cognate-binding sites.
Amino acidsubstitutions inthe DNA-binding domain of the
v-Myb proteinof AMV abolishes bindingof theprotein to
Myb-binding site3of the 2.7kblysozyme enhancer
The data illustrated in Figure 1 demonstrated that
v-Myb
REV, in which most of the amino acid substitutions
found in the v-Myb protein of AMV had been reverted,
activated the  2.7kb lysozyme enhancer, while
v-Myb
AMV was unable to do so. Since our work had
shown Myb-binding site 3 to play a key role in the
activation of the enhancer, we wondered whether or not
v-Myb
AMV was able to bind to this site. In the light of the
current model of the Myb DNA-binding domain (37)
a direct eﬀect of the substitutions on DNA binding seemed
unlikely because the amino acid residues that have been
substituted in the DNA-binding domain of AMV v-Myb
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Figure 2. Chromatin-immunoprecipitation experiment. (A) Western
blot analysis of Myb expression in HD11-E cells grown in the presence
or absence of doxycyclin. The black arrow marks the v-Myb
REV
protein. (B) Chromatin immunoprecipitation experiment using HD11-E
cells grown in the presence (left part) or absence (right part) of
doxycyclin. Immunoprecipitation was carried out using two diﬀerent
Myb-speciﬁc antisera (lanes 1 and 2), non-immune serum (lane 3) or no
antiserum (lane 4). Lane 5 shows no-template controls and lane 6
shows input controls. PCR primers were speciﬁc for the lysozyme gene
promoter and the  2.7kb enhancer. PCR products were analyzed by
agarose gel electrophoresis.
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Figure 3. Synergistic activation of the  2.7kb enhancer by Myb, C/EBP and PU.1. (A) QT6 cells were transfected with the reporter gene pTATA or
pTATA-2.7 and diﬀerent combinations of expression vectors for v-Myb
REV, C/EBPa, C/EBPb and PU.1, as indicated at the bottom. To control the
transfection eﬃciencies, cells were additionally transfected with the b-galactosidase plasmid pCMVb. Cells were harvested 24h after transfection and
analyzed for luciferase and b-galactosidase activities. The columns show the average luciferase activity normalized to the b-galactosidase activity.
Thin lines show standard deviations. The numbers above the columns indicate the extent of synergy between Myb and C/EBPa, C/EBPb and PU.1,
respectively. These numbers were determined by dividing the luciferase activity observed in the presence of both factors together by the sum of the
luciferase activities observed for each factor alone. (B) QT6 cells were transfected with pTATA-2.7 and diﬀerent combinations of expression vectors,
as indicated at the bottom. Cells were analyzed as described in A. (C) C/EBPa, C/EBPb and recombinant protein constructs are shown schematically
at the top. QT6 cells were transfected with pTATA-2.7 and the expression vectors indicated below the columns. To control the transfection
eﬃciencies, cells were additionally transfected with the b-galactosidase plasmid pCMVb. Cells were analyzed as in (A).
7242 Nucleic Acids Research, 2007, Vol. 35, No. 21point away from the bound DNA. On the other hand, by
using artiﬁcial sites that were systematically altered in
certain positions of the Myb consensus binding motif
Brendeford et al. (38) have shown that the AMV-speciﬁc
amino acid substitutions indeed can have some eﬀect on
the DNA-binding activity of the Myb DNA-binding
domain. To investigate whether the amino acid substitu-
tions in the DNA-binding domain of AMV-v-Myb aﬀect
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Figure 4. Identiﬁcation of a functional Myb-binding site in the  2.7kb enhancer. (A) QT6 cells were transfected with the reporter gene pTATA-2.7
and expression vector for v-Myb
REV (wt-Myb), the N186A mutation of v-Myb
REV (mut-Myb) or empty expression vector (no Myb), as indicated
below the columns. To control the transfection eﬃciencies cells were additionally transfected with the b-galactosidase plasmid pCMVb. Luciferase
and b-galactosidase activities were determined 24h after transfection. The luciferase activity was normalized to the b-galactosidase activity and is
expressed in arbitrary units. The activity of the reporter gene in the absence of v-Myb was designated as 1. Thin lines show standard deviations. The
insert at the top shows a western blot analysis of v-Myb expression in cells transfected with the same expression vectors. (B) The ﬁgure at the top
illustrates the position of Ets (E), C/EBP (C) and potential binding sites for Myb (M) in the  2.7kb enhancer. The sequences of the four potential
Myb-binding sites are shown below. Results of reporter gene assays, performed in QT6 cells, are shown at the bottom. pTATA (no enh.), pTATA-
2.7 (wt) or derivatives of this plasmid carrying point mutations in one of the four Myb-binding sites (mut1-4) were transfected with expression vector
for v-Myb
REV. Transfections were analyzed as in (A). (C) Reporter gene assays were performed in QT6 cells using the full-length or a truncated
 2.7kb enhancer construct. Cells were additionally transfected with expression vector for v-Myb
REV (black bars) or empty expression vector (white
bars). Transfections were analyzed as in (A).
Nucleic Acids Research, 2007, Vol. 35, No. 21 7243the ability to recognize binding site 3 of the  2.7kb
enhancer, we performed electrophoretic mobility shift
assays using bacterially expressed v-Myb proteins contain-
ing or lacking AMV-speciﬁc amino acid substitutions
within the DNA-binding domain. The experiment shown
in Figure 6A demonstrated that bacterially expressed
v-Myb, lacking AMV-speciﬁc amino acid substitutions
within the DNA-binding domain, was indeed able to
recognize Myb-binding site 3 in vitro. Binding to this site
was weaker than to the Myb binding site A of the mim-1
promoter, which was expected because binding site 3 of
the lysozyme enhancer diﬀers signiﬁcantly from the Myb
consensus binding motif. Mutation of binding site 3
abolished binding of Myb, consistent with the observation
that mutation of this site abolished the activation of the
enhancer by Myb. In the experiment illustrated in
Figure 6B we compared the ability of both versions of
Myb to bind to the mim-1 A site and to Myb-binding site
3. Both proteins recognized the mim-1 A site equally well;
however, the v-Myb protein containing the AMV-speciﬁc
amino acid substitutions was virtually unable to bind to
Myb-binding site 3. This observation clearly demonstrated
that the amino acid substitutions in the DNA-binding
domain of AMV v-Myb have aﬀected the sequence
speciﬁcity of the protein in such a way that it no longer
recognizes Myb-binding site 3 of the lysozyme enhancer.
This lack of binding provides a straightforward explana-
tion for the inability of v-Myb
AMV to activate the
lysozyme enhancer.
DISCUSSION
For several reasons the chicken lysozyme gene is an
interesting model system to explore the molecular
mechanisms by which Myb activates the expression of
its target genes. First, the transcriptional regulation of the
lysozyme gene has been studied extensively before. Several
cis-acting elements, including the promoter, several
enhancers and a silencer have been characterized in
detail and a number of transacting factors binding to
these elements have been identiﬁed (26,27,32,39–43).
Secondly, lysozyme gene expression is stimulated by
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Figure 5. Myb-binding site 3 of the  2.7kb enhancer mediates cooperation of Myb with PU.1 and C/EBPa. QT6 cells were transfected with the
reporter genes indicted at the top and expression vectors for v-Myb
REV and C/EBPa, as shown at the bottom. The luciferase activity was normalized
with respect to the b-galactosidase activity and is expressed in arbitrary units. The activity of each reporter gene in the absence of v-Myb was
designated as 1. Thin lines show standard deviations.
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permitting it to address the mechanisms by which Myb
activates a target gene in a lineage-speciﬁc manner.
Thirdly, the lysozyme gene is activated by c-Myb and
the Gag-Myb-Ets protein encoded by the E26 virus, but
not by the highly oncogenic v-Myb protein of AMV (21).
The inability of AMV to aﬀect lysozyme gene expression
has been attributed to the amino acid substitutions present
in the DNA-binding domain of v-Myb. Analysis of the
mechanisms underlying the activation of the lysozyme
gene by Myb might therefore also provide further insight
into the molecular function of the Myb DNA-binding
domain and into how these oncogenic amino acid
substitutions modulate the activity of the protein.
The data presented here provide novel insight into three
major issues. First, our results strongly suggest that the
activation of the lysozyme gene by Myb is not mediated by
a single cis-acting element but by the concerted action of
Myb on at least two cis-regulatory regions of the gene.
Reporter gene assays as well as chromatin immunopreci-
pitation showed that Myb binds and activates the
promoter and the myeloid-speciﬁc  2.7kb enhancer of
the lysozyme gene. This is highly reminiscent of two
other Myb-regulated genes that we have studied recently,
the chicken mim-1 and C/EBPb genes. In both cases Myb
has been shown to act on the promoter and, in addition,
on a myeloid-speciﬁc enhancer located in the vicinity of
the gene (19,44). A dual activation mechanism of Myb
target genes, as exempliﬁed by these genes, therefore seems
to be a rather common phenomenon, at least for genes
that are activated by Myb in the myelomonocytic lineage.
The majority of studies that have addressed the mecha-
nisms by which Myb regulates the expression of its targets
have focused on the promoters of these genes; it is
therefore possible that these studies so far have revealed
only part of the complexity of gene regulation by Myb.
It will be very interesting to explore if additional
Myb-dependent cis-regulatory elements are also present
in other Myb-regulated genes, particularly in genes
whose activation by Myb is not restricted to the
myelomonocytic lineage.
Secondly, our work provides insight into the lineage-
speciﬁcity of the Myb-dependent activation of the
lysozyme gene. We have identiﬁed C/EBPa and PU.1 as
cooperation partners of Myb at the promoter and the
 2.7kb enhancer of the lysozyme gene. C/EBPs have been
shown before to play important roles at the lysozyme
promoter and the  2.7kb enhancer, and PU.1 was shown
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Figure 6. Electrophoretic mobility shift experiments. (A) Western blot analysis of the bacterially expressed v-Myb
REV and v-Myb
AMV proteins. The
amounts (in ml) loaded onto the gel are shown at the bottom. Full-length Myb protein is marked by an arrow. (B) Binding reactions contained the
radiolabeled double-stranded oligonucleotides shown and bacterially expressed Myb protein, as indicated above and below the lanes. The numbers
below the lanes refer to the amounts (in ml) of protein added. Control reactions contained no Myb protein. Protein–DNA complexes were visualized
by electrophoresis on native polyacrylamide gels followed by autoradiography. The black and white arrowheads mark complexes of full-length v-
Myb and a proteolytic degradation product, respectively.
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activity (26,32,33). The cooperation of Myb with C/EBPa
and PU.1, which are known to regulate the expression of
numerous genes during myeloid diﬀerentiation, provides a
straightforward explanation for the observation that Myb
activates the lysozyme gene speciﬁcally in myeloid cells.
An interesting aspect of our work is that PU.1 and
C/EBPa apparently do not activate the lysozyme enhancer
synergistically in the absence of Myb. However, when
Myb is present synergy of all three factors is observed.
This suggests that Myb which occupies a central position
between C/EBPa and PU.1-binding sites orchestrates the
function of these proteins. How this is done is not clear at
present. It is possible that Myb directly interacts with
these proteins or that a bridging protein such as p300/CBP
is involved. Another interesting side aspect of our work
concerns the cooperation of Myb with diﬀerent members
of the C/EBP family. Myb is able to synergize with
diﬀerent C/EBP factors; for example, the promoter of the
mim-1 gene is synergistically activated by Myb together
with C/EBPa or C/EBPb (17). However, transcriptional
synergy at the lysozyme gene appears to be biased towards
C/EBPa. This might explain our observation that ectopic
expression of Myb and C/EBPa but not of Myb and
C/EBPb was suﬃcient to activate the expression of the
endogenous lysozyme gene in chicken ﬁbroblasts (17). The
poor performance of C/EBPb as a cooperation partner
of Myb appears not to be due to ineﬃcient binding of
C/EBPb, because C/EBPb was clearly able to activate the
lysozyme promoter and  2.7kb enhancer on its own.
Also, exchanging the DNA-binding domains between
C/EBPa and C/EBPb did not improve the ability of
C/EBPb to synergize with Myb. Apparently, the transac-
tivation domain of C/EBPa is crucial for the cooperation
with Myb in the context of the lysozyme enhancer and
cannot be replaced by the transactivation domain of
C/EBPb. Clearly, further work is needed to understand
why C/EBPb performs only poorly as a cooperation
partner of Myb at the lysozyme enhancer.
Thirdly, our work sheds new light on the role of the
oncogenic amino acid substitutions in the v-Myb protein
of AMV. Although truncation at either end of c-Myb was
shown to be suﬃcient to activate its oncogenic potential
the transforming capacity of the v-Myb protein of AMV
has been signiﬁcantly increased by a number of amino acid
substitutions (20). These substitutions are located in the
DNA-binding domain and other parts of the protein and
have apparently arisen during the repeated passage of the
virus in leukemic chickens, which were selected for the
high oncogenic potential of the virus (20). Several studies
addressing the impact of these mutations on Myb have
suggested diﬀerent aspects of the protein’s function to be
aﬀected by these substitutions. For example, it has been
demonstrated that the amino acid substitutions disrupt a
negative regulatory mechanism that is based on confor-
mational changes catalyzed by the peptidyl-prolyl-
isomerase Cyp-40 (22), or ability of v-Myb to cooperate
with the CCAAT-box/enhancer-binding protein C/EBPb
(23). More recently, the oncogenic amino acid substitu-
tions were reported to aﬀect the ability of Myb to interact
with the amino terminal tail of histone H3 and to facilitate
H3 acetylation (24). Furthermore, our own work has
previously shown that the cooperation of the mim-1
promoter and enhancer is aﬀected by the substitutions
(19). There is only one report which has implicated the
amino acid substitutions in altered DNA-binding proper-
ties by showing that the AMV-speciﬁc amino acid
substitutions result in less stable protein–DNA complexes
when certain binding sites were used (38), however, since
these experiments were performed in vitro using artiﬁcial
binding sites it was not clear whether they are relevant for
the activation of physiological Myb target genes. Our
analysis of the lysozyme gene shows for the ﬁrst time that
the oncogenic amino acid substitutions in the Myb DNA-
binding domain, aﬀect the DNA-binding properties of the
protein at a physiological target gene. It appears that the
AMV-speciﬁc amino acid substitutions result in a subtle
change of the sequence speciﬁcity of the Myb DNA-
binding domain, which impedes the binding of v-Myb to
the central Myb-binding site in the lysozyme enhancer.
Our data clearly show that the lack of binding to the
lysozyme enhancer is not due to a generally reduced
DNA-binding activity, because binding to the Myb
binding site from the mim-1 promoter was unaﬀected.
The amino acid substitutions of AMV v-Myb have been
selected to increase the oncogenic potential of v-Myb;
therefore, it appears likely that altered DNA binding
contributes to the oncogenicity of v-Myb. Recently, Liu
et al. (16) have identiﬁed a number of genes that are
diﬀerentially regulated by Myb proteins that have been
engineered to carry subsets of the AMV-speciﬁc amino
acid substitutions. It will be interesting to explore whether
altered DNA-binding properties also play a role in the
diﬀerential activation of these genes by v-Myb and c-Myb.
In a somewhat broader sense, it is surprising that the
amino acid substitutions in the DNA-binding domain of
v-Myb aﬀect seemingly unrelated properties of v-Myb,
such as DNA binding and various protein–protein
interactions. This emphasizes the central role of this
domain for Myb protein function.
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